epilepsiaEpilepsy and paroxysmal conditionsЭпилепсия и пароксизмальные состояния2077-83332311-4088IRBIS LLCepilepsia-462Research ArticleRESOLUTIONРЕЗОЛЮЦИЯРезолюция заседания экспертов рабочей группы Российской Противоэпилептической ЛигиРезолюция заседания экспертов рабочей группы Российской Противоэпилептической Лиги (5 марта 2019 г., Москва)РедакционнаястатьяEditorialArticle20192704201911197100Copyright © Editorial a., 20192019Редакционная с.Editorial a.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epilepsia.su/jour/article/view/462
.
.
ReferencesGlobal burden of epilepsy and the need for coordinated action at the country level to address its health, social and public knowledgeGlobal burden of epilepsy and the need for coordinated action at the country level to address its health, social and public knowledge implications, WHA Resolution, 26 May 2015 http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_R20-ru.pdf , dostup dekabr' 2015.implications, WHA Resolution, 26 May 2015 URL: http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_R20-ru.pdf , доступ декабрь 2015.Schiller Y., Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology. 2008; 70: 54-65.Schiller Y., Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology. 2008; 70: 54-65.Kwan P. et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010; 1: 1069-77.Kwan P. et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010; 1: 1069-77.Guekht A., Hauser W.A., Milchakova L., Churillin Y., Shpak A., Gusev E.The epidemiology of epilepsy in the Russian Federation. Epilepsy Res. 2010 Dec; 92 (2-3): 209-18.Guekht A., Hauser W. A., Milchakova L., Churillin Y., Shpak A., Gusev E. The epidemiology of epilepsy in the Russian Federation. Epilepsy Res. 2010 Dec; 92 (2-3): 209-18.Rudakova I.G., Vlasov P.N., Lipatova L.V., Voronkova K.V. Lacosamide (vimpat). Prospects for clinical application. Zhurnal nevrologii i psixiatrii im. S.S. Korsakova. 2017; 9: 147-152. (in Russ). https://doi.org/10.17116/jnevro201711791147-152.Рудакова И. Г., Власов П. Н., Липатова Л. В., Воронкова К. В. Лакосамид (Вимпат). Перспективы клинического применения. Журнал неврологии и психиатрии им. С. С. Корсакова. 2017; 9: 147-152. (in Russ). https://doi.org/10.17116/jnevro201711791147-152.Curia G., Biagini G., Perucca E. et al. Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009; 23 (7): 555-568.Curia G., Biagini G., Perucca E. et al. Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs 2009; 23 (7): 555-568.Errington A.C., Stohr T., Heers C., Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008; 73 (1): 157-169.Errington A. C., Stohr T., Heers C., Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008; 73 (1): 157-169.Panayiotopoulos C. P. Principles of therapy in the epilepsies. A Clinical Guide to Epileptic Syndromes and their Treatment. Springer London. 2010; 173-235.Panayiotopoulos C. P. Principles of therapy in the epilepsies. A Clinical Guide to Epileptic Syndromes and their Treatment. Springer London. 2010; 173-235.Baulac M., Rosenow F., Toledo M., Terada K., Li T., De Backer M., Werhahn K. J., Brock M. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2017; 16: 43-54.Baulac M., Rosenow F., Toledo M., Terada K., Li T., De Backer M., Werhahn K. J., Brock M. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2017; 16: 43-54.Brodie M.J. et al. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013; 54: 11-27.Brodie M. J. et al. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013; 54: 11-27.Vlasov P.N., Kamelkova E.G., Drozzhina F.R. Efficacy and tolerance of intravenous lacosamide in urgent neurological situations. Neurology, Neuropsychiatry, Psychosomatics. 2012; 4 (1S): 60-63. (In Russ.) https://doi.org/10.14412/2074-2711-2012-2501.Власов П. Н., Камелькова Е. Г., Дрожжина Г. Р. Эффективность и переносимость лакосамида для внутривенного введения при ургентных неврологических ситуациях. Cпецвыпуск Эпилепсия. Неврология, нейропсихиатрия, психосоматика. 2012; (1S): 60-3. https://doi.org/10.14412/2074-2711-2012-2501.Vlasov P.N. Intravenous Antiepileptic Drugs in Russia. Neurology, Neuropsychiatry, Psychosomatics. 2014; 6 (1S): 48-53. (In Russ.) https://doi.org/10.14412/2074-2711-2014-1S-48-53.Власов П. Н. Внутривенные формы противоэпилептических препаратов в России. Неврология, нейропсихиатрия, психосоматика. 2014; (1S): 48-53. https://doi.org/10.14412/2074-2711-2014-1S-48-53.Vlasov P.N., Shaxabasova Z.S., Filatova N.V. Epilepsy first occured in elderly patients: diagnosis, differential diagnosis, therapy. Farmateka. 2010; 7: 40-47. (In Russ.). eLIBRARY ID: 15103356.Власов П. Н., Шахабасова З. С., Филатова Н. В. Эпилепсия, впервые выявленная у пожилых пациентов: диагностика, дифференциальная диагностика, терапия. Фарматека. 2010; 7: 40-47. eLIBRARY ID: 15103356.Karlov V.A., Gext A.B., Guzeva V.I., Lipatova L.V., Bazilevich S.N., Mkrtchan V.R., Vlasov P.N., Zhidkova I.A., Muxin K.Yu., Petruxin A.S., Lebedeva A.V. Algorithms of mono- and polytherapy in clinical epileptology. Zhurnal nevrologii i psixiatrii im. S.S. Korsakova. 2016; 7: 120-129. (In Russ.). eLIBRARY ID: 26469142.Карлов В. А., Гехт А. Б., Гузева В. И., Липатова Л. В., Базилевич С. Н., Мкртчан В. Р., Власов П. Н., Жидкова И. А., Мухин К. Ю., Петрухин А. С., Лебедева А. В. Алгоритмы моно- и политерапии в клинической эпилептологии. Часть 2. Особенности лечения отдельных групп пациентов. Журнал неврологии и психиатрии им. С. С. Корсакова. 2016; 7: 120-129. eLIBRARY ID: 26469142.Helmstaedter C., Witt J.A. The longer-term cognitive effects of ajunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting. Epilepcy & Behavior. 2013; 26: 182-187. https://doi.org/10.1016/j.yebeh.2012.11.052.Helmstaedter C., Witt J.A. The longer-term cognitive effects of ajunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting. Epilepcy & Behavior. 2013; 26: 182-187. https://doi.org/10.1016/j.Moseley B.D., Cole D., Iwuora O., Strawn J.R., Privitera M. The effects of lacosamide on depression and anxiety in patients with epilepsy. Epilepsy Research. 2015; 110: 115-118. https://doi.org/10.1016/j.eplepsyres.2014.1012.1007.yebeh.2012.11.052.yebeh.2012.11.052.Moseley B.D., Cole D., Iwuora O., Strawn J.R., Privitera M. The effects of lacosamide on depression and anxiety in patients with epilepsy. Epilepsy Research. 2015; 110: 115-118. https://doi.org/10.1016/j.eplepsyres.2014.1012.1007.Moseley B.D., Cole D., Iwuora O., Strawn J.R., Privitera M. The effects of lacosamide on depression and anxiety in patients with epilepsy. Epilepsy Research. 2015; 110: 115-118. https://doi.org/10.1016/j.eplepsyres.2014.1012.1007.
The authors declare that there are no conflicts of interest present.